Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17
Open Access
- 27 August 2010
- Vol. 117 (1) , 48-53
- https://doi.org/10.1002/cncr.25580
Abstract
BACKGROUND: The current study was performed to determine the impact of polysomy 17 on the interpretation of HER2 testing of invasive breast carcinomas using fluorescent in situ hybridization methods. Current American Society of Clinical Oncology/College of American Pathologists guidelines define HER2‐positive tumors as those with >6 HER2 genes per nucleus or those with HER2/CEP17 (chromosome 17) ratio >2.2. These guidelines are potentially contradictory in tumors with polysomy of chromosome 17.METHODS: Seventy‐two breast carcinoma cases with reported polysomy of chromosome 17 (≥3 CEP17 signals on average) by fluorescent in situ hybridization were identified, and the corresponding HER2 immunohistochemistry was obtained. The HER2 status of the archived samples was reviewed, and the tumors were recategorized according to the 2007 American Society of Clinical Oncology/College of American Pathologists guidelines.RESULTS: The average CEP17 copy number for the group was 4.5 (range, 3.0‐10.4). Thirty‐three (45.8%) cases had >6 copies of HER2 per nucleus. Twenty‐one cases (29.2%) qualified as HER2 gene amplified using the HER2/CEP17 ratio (>2.2) guideline. All these cases had >6 HER2 signals, which represented 63.6% of all cases with >6 HER2 signals. HER2 protein expression showed significant positive correlations with both HER2 gene copy number and HER2/CEP17 ratio (P < .01, rs = 0.56 and 0.64, respectively).CONCLUSIONS: Increased CEP17 signals detected in invasive breast carcinomas may lead to discordant interpretation of gene amplification in a significant proportion of the cases, depending on which criterion (ratio vs absolute number) is used for interpretation. However, increased gene dosage (>6 HER2 genes or HER2/CEP17 ratio >2.2), regardless of the evaluation method, is positively correlated with HER2 protein expression. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breastLaboratory Investigation, 2010
- Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast CancerPathobiology, 2010
- Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)The Lancet Oncology, 2010
- Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplificationBreast Cancer Research and Treatment, 2009
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsJournal of Clinical Oncology, 2009
- Treatment of metastatic breast cancer: looking towards the futureBreast Cancer Research and Treatment, 2008
- Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumorsLaboratory Investigation, 2008
- Optimization of the Affymetrix GeneChip Mapping 10K 2.0 Assay for Routine Clinical Use on Formalin-fixed Paraffin-embedded TissuesDiagnostic Molecular Pathology, 2008
- The effect of chromosome 17 polysomy on HER-2/neu status in breast cancerJournal of Clinical Pathology, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007